Agoston Gyula Szabo, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Carsten Helleberg, Emil Hermansen, Søren Thorgaard Bønløkke, Katrine Nielsen, Elena Manuela Teodorescu, Eva Kurt, Casper Nørgaard Strandholdt, Annette Juul Vangsted. The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.EJHaem. 2023, 4 (4): 1006-1012
Diana Beatriz Bayani, Yihao Clement Lin, Melissa G Ooi, Allison Ching Yee Tso, Hwee Lin Wee. Real-world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore.EJHaem. 2023, 4 (4): 1013-1018
Heidi Loponen, Juha Mehtälä, Tero Ylisaukko-Oja, Oscar Brück, Kimmo Porkka, Perttu Koskenvesa, Kirsi Saukkonen, Juha Lievonen. Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland.EJHaem. 2023, 4 (4): 1019-1029
Maoqin Li, Haihao Lu, Jiaoyang Fan, Min Dai, Chang Su. A nomogram prognostic model for diffuse large B-cell lymphoma based on SUVmax and GNRI in elderly patients.EJHaem. 2023, 4 (4): 1030-1041
Lale Kostakoglu, Maurizio Martelli, Laurie H Sehn, Andrew Davies, Marek Trněný, Michael Herold, Umberto Vitolo, Wolfgang Hiddemann, Judith Trotman, Andrea Knapp, Federico Mattiello, Tina G Nielsen, Deniz Sahin, Gila Sellam, Carol Ward, Anas Younes. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.EJHaem. 2023, 4 (4): 1042-1051
Rocío Vila, Alba Rubio-San-Simón, Pablo Zubiaur, Marcos Navares-Gómez, Patricia Gómez-Hernández, Begoña Arce, Luis Madero. Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.EJHaem. 2023, 4 (4): 1052-1058
Shyam A Patel, Jan Cerny, William K Gerber, Muthalagu Ramanathan, Asiri Ediriwickrema, Benjamin Tanenbaum, Lloyd Hutchinson, Xiuling Meng, Julie Flahive, Bruce Barton, Andrew J Gillis-Smith, Sakiko Suzuki, Salwa Khedr, William Selove, Anne W Higgins, Patricia M Miron, Karl Simin, Bruce Woda, Jonathan M Gerber. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with disruptions.EJHaem. 2023, 4 (4): 1059-1070
Lai Yee Orbell, Nouf Abutheraa, Andrew S Duncombe, Mary Frances McMullin, Ruben Mesa, Charlene M McShane, Glen James, Lesley A Anderson. The mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden.EJHaem. 2023, 4 (4): 1071-1080
Marta Ligero, Marc Simó, Cecilia Carpio, Gloria Iacoboni, Maria Balaguer-Montero, Victor Navarro, Mario Andres Sánchez-Salinas, Sabela Bobillo, Ana Marín-Niebla, Josu Iraola-Truchuelo, Pau Abrisqueta, Roser Sala-Llonch, Francesc Bosch, Raquel Perez-Lopez, Pere Barba. PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.EJHaem. 2023, 4 (4): 1081-1088
Pierre Peterlin, Marie C Béné, Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Alice Garnier, Camille Debord, Marion Eveillard, Patrice Chevallier. Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients.EJHaem. 2023, 4 (4): 1089-1095
D Sorcini, A Stella, A Scialdone, S Sartori, A Marra, R Rossi, F De Falco, F M Adamo, E Dorillo, C Geraci, R Arcaleni, C Rompietti, A Esposito, L Moretti, M G Mameli, M P Martelli, B Falini, P Sportoletti. FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia.EJHaem. 2023, 4 (4): 1100-1104
Sean Harrop, Phillip C Nguyen, David Byrne, Clarissa Wilson, Georgina L Ryland, Tamia Nguyen, Mary Ann Anderson, Seong Lin Khaw, Michelle Martin, Ing Soo Tiong, Elaine Sanij, Piers Blombery. Persistence of tandem duplications in remission in acute myeloid leukaemia.EJHaem. 2023, 4 (4): 1105-1109
Marc S Raab, Elena Zamagni, Salomon Manier, Paula Rodriguez-Otero, Fredrik Schjesvold, Annemiek Broijl. Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.EJHaem. 2023, 4 (4): 1117-1131
Gaël Vermeersch, Timothy Devos, Helena Devos, Frédéric Lambert, Bruce Poppe, Sam Van Hecke. Germline heterozygous SH2B3-mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation.EJHaem. 2023, 4 (4): 1143-1147